ArticleEndocrine2026
Overlap between body mass index- and height-adjusted sarcopenic obesity and their association with functional capacity in older adults with diabetes: A study based on the JWGSO consensus.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo examine the overlap of sarcopenic obesity (SO), defined by two different diagnostic criteria, in older adults with diabetes and to investigate its association with higher-level functional capacity.
methodsWe conducted a cross-sectional study using retrospective data from patients with diabetes aged ≥ 60 years who were hospitalized at Ise Red Cross Hospital, irrespective of diabetes type, disease duration, and diabetes-related complications. The data collection period was one year, beginning in July 2020. SO was assessed using the criteria of the Japanese Working Group on Sarcopenic Obesity (JWGSO), which adjusts muscle mass by body mass index; the Asian Working Group for Sarcopenia 2019 (AWGS), which adjusts muscle mass by height; and body fat percentage. Body fat percentage and skeletal muscle mass were measured using multi-frequency bioelectrical impedance analysis. Higher-level functional capacity was evaluated using the Tokyo Metropolitan Institute of Gerontology Index of Competence. Using multiple regression analysis, we calculated the standardized partial regression coefficient (β) for the association between SO and higher-level functional capacity, adjusting for age, gender, diabetes etiology, HbA1c, number of comorbidities, living alone, mild cognitive decline, and diabetic medications. The estimated sample size was approximately 300 patients.
resultsThe study included 345 patients; 61 (17.6%) met JWGSO-SO and 51 (14.7%) met AWGS-SO, with approximately half of them overlapping. The adjusted β for higher-level functional capacity of JWGSO-SO+/AWGS-SO−, JWGSO-SO+/AWGS-SO+, and JWGSO-SO−/AWGS-SO+, with JWGSO-SO−/AWGS-SO − as the reference, was − 0.131 (P = 0.031), − 0.064 (P = 0.289), and − 0.031 (P = 0.590), respectively.
conclusionAbout half of the patients with SOs overlapped between the two criteria. Additionally, a significant association was observed between JWGSO-SO and decreased higher-level functional capacity.
Indexed as
Identifiers
42043627What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.